Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nextgem Inc. is currently focused on the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action, which represents the current scope of the company's active prosecution. This 1 pending office action indicates a targeted approach to securing intellectual property rights in the Biotechnology & Pharmaceuticals sector.
The prosecution is concentrated within 1 distinct art unit and involves 1 distinct examiner. This level of concentration suggests that the company's current applications are being evaluated within a specific technical and administrative framework. For a practitioner, the involvement of 1 distinct examiner means that the prosecution strategy is not spread across different perspectives at the patent office.
PENNINGTON, KATIE LEIGH is the busiest examiner for the portfolio, with a busiest examiner pending count of 1. This examiner is responsible for the 1 pending office action currently active. The success of the company's pending matters is closely tied to the examination style of PENNINGTON, KATIE LEIGH, who is the 1 examiner identified. Practitioners should monitor the actions of PENNINGTON, KATIE LEIGH to anticipate the next steps for this portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014112 | HUMAN LONG-TERM HEMATOPOIETIC STEM CELL MARKER | PENNINGTON, KATIE LEIGH | 24d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014112 | HUMAN LONG-TERM HEMATOPOIETIC STEM CELL MARKER | PENNINGTON, KATIE LEIGH | 24d overdue |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18014112 | HUMAN LONG-TERM HEMATOPOIETIC STEM CELL MARKER | PENNINGTON, KATIE LEIGH | 1634 | §103 | Final Rejection | 24d overdue | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial